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a  b  s  t  r  a  c  t
Lipoprotein(a)  (Lp(a))  is  an  independent  risk  factor  for the  development  of  cardiovascular  disease.  Vas-
cular  smooth  muscle  cell  (SMC)  motility  and  plasticity,  functions  that  are  inﬂuenced  by environmental
cues,  are  vital  to adaptation  and  remodelling  in vascular  physiology  and  pathophysiology.  Lp(a)  is
reportedly  damaging  to SMC  function  via  unknown  molecular  mechanisms.  Apolipoprotein(a)  (apo(a)),
a  unique  glycoprotein  moiety  of Lp(a),  has been  demonstrated  as its active  component.  The aims  of
this  study  were  to  determine  functional  effects  of  recombinant  apo(a)  on human  vascular  SMC  motil-
ity  and  explore  the underlying  mechanism(s).  Exposure  of SMC  to  apo(a)  in  migration  assays  induced
a  potent,  concentration-dependent  chemorepulsion  that was  RhoA  and  integrin  V3-dependent,  butigration
hoA
emodelling
transforming  growth  factor  -independent.  SMC  manipulation  through  RhoA  gene  silencing,  Rho  kinase
inhibition,  statin  pre-treatment,  V3 neutralising  antibody  and  tyrosine  kinase  inhibition  all  markedly
inhibited  apo(a)-mediated  SMC  migration.  Our  data  reveal  unique  and potent  activities  of  apo(a)  that
may  negatively  inﬂuence  SMC  remodelling  in  cardiovascular  disease.  Circulating  levels  of Lp(a)  are resis-
tant  to  lipid-lowering  strategies  and hence  a greater  understanding  of  the mechanisms  underlying  its
 may
 201functional  effects  on  SMC
©Abbreviations: Ao, aortic; -SMA, alpha smooth muscle actin; apo(a),
polipoprotein(a); DMEM,  Dulbecco’s modiﬁed eagle medium; ERK, extracellular
ignal-regulated  kinase; FCS, foetal calf serum; GAPDH, glyceraldehyde 3-phosphate
ehydrogenase;  HP, high power; Lp(a), lipoprotein(a); MAPK, mitogen activated
rotein kinase; NFB, nuclear factor kappa B; PDGF, platelet-derived growth factor-
B; ROCK, Rho kinase; SV, saphenous vein; SMC, smooth muscle cell; TGF,
ransforming  growth factor beta.
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1. Introduction
Lipoprotein(a) (Lp(a)) is a plasma glycoprotein expressed only
in humans and some primates, and Lp(a) concentration is an inde-
pendent risk factor for cardiovascular disease (Marcovina et al.,
2003). Plasma concentrations of Lp(a) are genetically determined
and although there is considerable variation in circulating levels
within the population (<10 to >100 mg/dL), levels remain relatively
constant throughout an individual’s lifetime. Unlike cholesterol,
Lp(a) is resistant to modulation by lipid-lowering strategies such
as statins or to lifestyle changes including diet, exercise or smok-
ing (Pena-Diaz et al., 2000). There are currently no speciﬁc and
effective pharmacological therapeutics for Lp(a), indicating a clear
Open access under CC BY-NC-ND license.rationale for their development (reviewed in Tsimikas and Hall,
2012). Plasma concentrations greater than 20 mg/dL are indicative
of a ∼2-fold increased risk of developing cardiovascular disease
such as atherosclerosis and vein graft failure, and importantly
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hese levels are evident in approximately 25% of the popula-
ion (Dahlen et al., 1986; Danesh et al., 2000; Koschinsky et al.,
991). Importantly, plasma concentrations of Lp(a) are elevated
n patients with familial hypercholesterolaemia (FH) (Kraft et al.,
000) and Lp(a) is an independent predictor for the develop-
ent of coronary heart disease in patients with FH (Seed et al.,
990).
The structure of Lp(a) has been thoroughly described (Pena-Diaz
t al., 2000), comprising an LDL-apoB-100 core covalently linked to
polipoprotein(a) (apo(a)). The copy number of kringle IV type 2 in
po(a) is variable and inversely correlated with Lp(a) plasma con-
entration (Frank et al., 1996; Koschinsky et al., 1991). In addition to
opy number, single nucleotide polymorphisms within the apo(a)
ene associate with the variation in circulating Lp(a) levels (Clarke
t al., 2009).
A  cognate receptor for Lp(a) has not been identiﬁed although
t has been shown to signal through the integrins V3 and M2
n some cell types (Liu et al., 2009; Sotiriou et al., 2006). Another
ossible mode of action of Lp(a) (through the apo(a) moiety) is
y decreasing the formation of active transforming growth fac-
or beta (TGF) (Liu et al., 2009; O’Neil et al., 2004). Additionally,
ctivation of intracellular signalling pathways such as extracellu-
ar signal-regulated kinase (ERK), p38 mitogen activated protein
inase (MAPK) (Liu et al., 2009), nuclear factor kappa B (NFB)
Sotiriou et al., 2006) and RhoA (Cho et al., 2008; Pellegrino et al.,
004) have been reported. Functionally, this can manifest as mod-
lation of cell proliferation and migration (Komai et al., 2002; Liu
t al., 2009; O’Neil et al., 2004; Syrovets et al., 1997; Yu et al., 2003).
Vascular remodelling (through increased cellular proliferation
nd/or migration) plays a key role in the development of cardio-
ascular disease and vein graft adaptation. Whilst the causes of
therosclerosis are complex and multifactorial, plasma Lp(a) lev-
ls are correlated with the degree of carotid atherosclerosis in
troke patients (Nasr et al., 2011). Furthermore, immunoreactivity
or apo(a) has been demonstrated in human coronary and carotid
therosclerotic lesions and the adjacent intima (Cushing et al.,
989; Haque et al., 2000). Lp(a) has been shown to inﬂuence mul-
iple cell types including inﬂammatory cells, platelets, endothelial
ells and smooth muscle cells (SMC) by modulating their function
n a manner that compromises vascular health (reviewed in Riches
nd Porter, 2012). Although pro-inﬂammatory (Sotiriou et al., 2006;
simikas et al., 2003) and mitogenic (Kojima et al., 1991; Komai
t al., 2002) actions of apo(a) on human aortic SMC  function have
een described, a full characterisation of its effects on vascular SMC
otility and phenotype have not been determined. In this study
e used in vitro methods to reveal novel, but potentially adverse
ffects of recombinant human apo(a) on vascular SMC motility and
lucidate the underlying molecular mechanisms.
. Materials and methods
.1.  Reagents
Recombinant 17K-apo(a) was prepared in the laboratory of
rof. ML  Koschinsky, University of Windsor, Ontario. In brief, the
rotein was puriﬁed from a stably expressing cell line, exten-
ively characterised and found to be highly comparable to the
po(a) derived from Lp(a) (Koschinsky et al., 1991). Moreover,
ontamination from LPS has not been detected in routine testing.
ell culture reagents were from Invitrogen except foetal calf
erum (FCS) which was from BioSera. Boyden chambers were
rom BD Biosciences and platelet-derived growth factor-BB (PDGF)
as from Sigma–Aldrich. Primary antibodies were from Cell
ignaling Technology (phospho-Smad2 (Ser465/467), phospho-
RK (Thr202/Tyr204) and total ERK), Santa Cruz (RhoA), AbCamistry & Cell Biology 45 (2013) 1776– 1783 1777
(-actin  and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH)) and Sigma–Aldrich (alpha smooth muscle actin (-
SMA)). Neutralising antibodies against TGFRII (AF-241-NA) and
integrin V3 (MAB1976 clone LM109) were from R&D Systems
and Millipore respectively. Fluorescent nuclear, cytoplasmic and
F-actin stains were from Invitrogen. G-LISA RhoA Activation Assay
Biochem Kit was from Cytoskeleton Inc. RhoA siRNA was from
Dharmacon and Lipofectamine 2000 transfection reagent from
Invitrogen. Rho kinase (ROCK) inhibitor Y-27632 and ﬂuvastatin
were from Calbiochem.
2.2.  Cell culture
Saphenous vein (SV) and aortic (Ao) specimens were obtained
from patients undergoing elective coronary artery bypass graft
surgery at the Leeds General Inﬁrmary. Local research ethics com-
mittee approval (Leeds West, CA/01/040) and informed, written
patient consent were obtained. The investigation conformed to the
principles outlined in the Declaration of Helsinki. SMC  were cul-
tured by explant technique as described previously (Porter et al.,
2002). Brieﬂy, vessel fragments were diced within a 2 mL  volume
of Dulbecco’s modiﬁed eagle medium (DMEM) containing 10% FCS,
transferred to tissue culture ﬂasks and maintained in a tissue cul-
ture incubator at 37 ◦C, 5% CO2 in air. Following 1–2 weeks of
culture, SMC  were observed migrating out from the tissue. Once
conﬂuent, SMC  were cultured in media containing 10% FCS and
passaged using trypsin/EDTA as required. All experiments were
performed on early passage cells (P3-P6) from different patients.
2.3.  Migration assays
In  vitro migratory properties were assessed as described previ-
ously using a modiﬁed Boyden chamber technique (Porter et al.,
2002) performed over 6 h. Serum-deprived cells (1 × 105) were
loaded in the upper chamber in basal medium comprising DMEM
with 0.4% FCS. The lower chamber contained basal medium alone
(control) or was supplemented with PDGF (10 ng/mL) as chemoat-
tractant. In further experiments the upper or lower chamber was
supplemented with 0–50 nM apo(a) as required. After incubation
for 6 h at 37 ◦C, duplicate membranes were ﬁxed, processed, stained
with Haematoxylin and Eosin and migrated cells were quantiﬁed
by counting cells in 10 random ﬁelds under high power (HP) light
microscopy (400×), as described previously (Porter et al., 2002).
2.4.  Immunoblotting
Serum-starved cells were treated with 25 nM apo(a) for
5–30 min  before preparing whole cell homogenates and
immunoblotting for phospho-Smad2 (Ser465/467), phospho-
ERK (Thr202/Tyr204), total ERK, RhoA or -actin as described
previously (Turner et al., 2001). In selected experiments, cells were
pretreated with increasing concentrations (0.3–30 g/mL) of a
TGF RII neutralising antibody prior to stimulation with 5 ng/mL
TGF for 20 min. In a separate series of experiments, SMC were
exposed to vehicle or 25 nM apo(a) for 6–48 h before preparing
whole cell homogenates and immunoblotting for -SMA and
GAPDH. Densitometric analysis was performed using a ﬂatbed
scanner and ImageQuant software (Amersham Life Sciences). Data
are presented as the ratio of densitometric analyses (mean ± SEM).
2.5. Immunoﬂuorescence microscopySMC were seeded in glass-bottomed 96-well plates at a den-
sity of 2 × 103/well in triplicate in full growth medium for 24 h
before serum depriving in basal medium for an additional 24 h.
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hey were then exposed ± 50 nM apo(a) for 24 h before ﬁxation in
% paraformaldehyde.
Fixed cells were treated with ﬂuorescent markers to stain the
ucleus (DAPI, 2 g/mL), cytoplasm (TOTO3, 1 M)  and the F-actin
ytoskeleton (rhodamine phalloidin, 1:40) in PBS. Stained cells
ere visualised using 20× objective on a Perkin Elmer Operetta
igh throughput ﬂuorescence microscope. Five images were taken
or each well (ﬁeld dimensions 675 m × 510 m).  Images were
nalysed using Perkin Elmer Harmony 3.0 software using custom
ade algorithms to deﬁne cell boundaries (accuracy of the deﬁned
ell boundaries was conﬁrmed by two observers). Cells overlap-
ing the edge of the image were excluded from the analysis. Cell
ebris was excluded from the analysis by ﬁltering out objects of less
han 1000 m2. Cells that had partially detached and folded over,
esulting in an artefactually high actin intensity, were removed
rom the analysis by ﬁltering out objects with an actin intensity
f greater than 800 arbitrary units. Read-outs were cell area and
ctin morphology (F-actin intensity and ridge frequency).
.6.  RhoA activity assay
Cells  were seeded at a density of 2 × 105 in 25 cm2 ﬂasks and
ultured for 3 days in DMEM with 10% FCS before being serum-
tarved for 48 h and then exposed to 25 nM apo(a) for 5–20 min.
hoA activity (i.e. GTP-bound RhoA) was measured using G-LISA
hoA Activation Assay according to manufacturer’s instructions.
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ig. 1. Effect of apo(a) on SMC  migration in a Boyden chamber (6 h). Changes are compa
ine). (A) Number of migrated cells per high power (HP) ﬁeld for SV-SMC and (B) aortic 
s. PDGF in lower chamber). (C) Chequerboard analysis of SV-SMC migration in the prese
lone  in lower chamber). (D) Chequerboard analysis in response to apo(a) alone (n = 6, ***istry & Cell Biology 45 (2013) 1776– 1783
2.7. RhoA gene silencing
SV-SMC  were transfected with 0 or 25 nM RhoA-targeted siRNA
(ON-TARGET plus SMARTpool Human RhoA, L-003860-00) with
the following sequences: CGACAGCCCUGAUAGUUUA; GACCAAA-
GAUGGAGUGAGA; GCAGAGAUAUGGCAAACAG; GGAAUGAUGAG-
CACACAAG, using Lipofectamine 2000 transfection reagent as
described previously (Turner et al., 2007). The efﬁciency of gene
silencing was  assessed by western blotting for RhoA as described
above.
2.8. Statistical analysis
Results  are expressed as mean ± SEM with n representing cells
from different patients except where otherwise indicated. Cell size
and actin morphology were analysed using a paired ratio t-test,
and all other data were analysed using one-way ratio ANOVA with
Newman–Keuls post hoc test (GraphPad Prism software). P < 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Effect of apo(a) on SMC  migrationSV-SMC  motility was investigated over a 6 h period using a modiﬁed Boyden
chamber  assay. PDGF added to the lower chamber signiﬁcantly increased migration
of cells from the upper chamber (Fig. 1A). Inclusion of 25 nM apo(a) in the lower
chamber  together with 10 ng/mL PDGF counteracted the chemotactic response.
Conversely, when apo(a) was  included in the upper chamber along with the cells,
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nce of PDGF (all n = 6, ***P < 0.001, **P < 0.01, *P < 0.05, NS = non-signiﬁcant vs. PDGF
P < 0.001, **P < 0.01 vs. control media in lower chamber).
K. Riches et al. / The International Journal of Biochemistry & Cell Biology 45 (2013) 1776– 1783 1779
Fig. 2. Concentration dependency of the effect of apo(a) on SMC  migration. Changes are compared to migration in the presence of PDGF in the lower chamber (horizontal
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hashed line). (A) Representative images of Boyden chamber assays (PDGF = 10 ng/
po(a) was included in the lower chambers (**P < 0.01 ANOVA for effect of apo(a)) o
*P  < 0.01, ***P < 0.001 vs. PDGF alone in lower chamber).
 markedly augmented PDGF response was  observed, indicating that apo(a) was
cting as a chemorepellent (Fig. 1A). This chemorepellent activity was apparent in
MC from both aortic and venous sources although the magnitude of response was
maller in Ao-SMC (Fig. 1A and B), and was  independent of length of time in cul-
ure/passage number (Supplementary Fig. 1). Using PDGF as a chemoattractant, we
erformed a chequerboard analysis of apo(a) on SV-SMC and observed consistent
hemorepulsion  irrespective of its location (upper or lower chamber). However in
he absence of a concentration gradient (i.e. apo(a) in both the upper and lower
hambers,  with PDGF in the lower chamber), the number of migrated cells was
omparable  to that observed with PDGF alone (Fig. 1C). Furthermore, this directional
ffect was  apparent even in the absence of PDGF, indicating that the chemorepellent
ctivity  of apo(a) was  independent of PDGF (Fig. 1D).
Supplementary data related to this article found, in the online version, at
ttp://dx.doi.org/10.1016/j.biocel.2013.05.021.
To explore the concentration-dependency of the apo(a) effect, SV-SMC were
tudied  in Boyden assays with increasing concentrations of apo(a) (1–50 nM)  in the
pper or lower wells. Fig. 2A shows representative images of Boyden chamber mem-
ranes with cell nuclei indicated. When apo(a) was included in the lower chamber,
DGF-induced  chemotaxis was attenuated in a concentration-dependent manner
Fig. 2A and B). Inclusion of 10 nM apo(a) was sufﬁcient to completely negate the
hemotactic effect of PDGF, which was reduced further (below basal levels) at higher
oncentrations of apo(a) (Fig. 2B). Conversely, inclusion of apo(a) in the upper cham-
er enhanced the chemotactic response to PDGF by two-fold at 25 nM apo(a) (Fig. 2A
nd C).
.2. Apo(a) effects are independent of TGF  ˇ and ERK signalling
Apo(a) is reported to induce functional cellular effects via inhibition of the TGF
ctivation  pathway (Liu et al., 2009; O’Neil et al., 2004). Pre-treatment of SV-SMC
ith  10 g/mL TGF RII neutralising antibody prevented TGF signalling, as demon-
trated  by a loss of TGF-induced Smad2 phosphorylation (Fig. 3A). Inclusion of the
eutralising antibody in the Boyden chamber assay failed to modulate SMC migra-
ion, irrespective of the stimulus (Fig. 3B), indicating that the effects of apo(a) were
GF-independent. Apo(a) is also reported to activate ERK signalling, yet in SV-SMC
xposure  to apo(a) alone consistently failed to increase ERK-1/2 phosphorylation
bove  basal levels (Fig. 3C). Importantly, PDGF induced robust phosphorylation of
RK-1/2, conﬁrming functionality of this pathway in SV-SMC (Supplementary Fig.
). However, apo(a) (1–50 nM)  did not modulate this PDGF-induced ERK phosphor-
lation  (Supplementary Fig. 2).
Supplementary data related to this article found, in the online version, at
ttp://dx.doi.org/10.1016/j.biocel.2013.05.021.o(a) = 25 nM,  scale bar = 50 m). Number of migrated cells per HP ﬁeld when (B)
pper chamber (all n = 5–6,***P < 0.001 ANOVA for effect of apo(a). Post hoc *P < 0.05,
3.3. RhoA/Rho kinase mediate the effects of apo(a)
The inﬂuence of apo(a) on SV-SMC morphology was  determined using high
throughput  immunoﬂuorescence microscopy. Application of apo(a) caused a sig-
niﬁcant 1.3-fold increase in spread cell area (Fig. 4A and B). Furthermore, apo(a)
induced  the formation of stress ﬁbres with a 1.2-fold increase in both the intensity
of  F-actin ﬁbres (Fig. 4C) and frequency of F-actin ﬁbre bundles (Fig. 4D). Alterations
in  cell area are often associated with a switch in phenotype from differentiated
(spindle  shaped) to dedifferentiated (rhomboid shaped); mirrored by reduced
expression  of -SMA (Owens et al., 2004). Therefore, to determine whether apo(a)
inﬂuenced  SMC  phenotype per se we  measured levels of -SMA in cells treated
over  a 6–48 h time period; however no differences were observed (Fig. 4E). RhoA
is  involved in stress ﬁbre formation and apo(a) has previously been reported to
induce RhoA activation in endothelial cells (Pellegrino et al., 2004; Cho et al., 2008),
so we examined whether a similar effect was seen in SV-SMC. Apo(a) induced rapid
activation of RhoA, which was signiﬁcant within 20 min  after application (Fig. 4F).
To  determine whether activation of the RhoA/ROCK pathway was responsible
for  the chemorepellent effects of apo(a), we employed RhoA gene silencing (siRNA).
Efﬁcient RhoA protein knock-down in SV-SMC was conﬁrmed by immunoblotting
(Fig.  5A). RhoA silencing had no effect on basal migration, but fully overcame the
modulatory effect of apo(a) (Fig. 5B). Similar results of RhoA siRNA were obtained
for  apo(a)-induced migration in the presence of PDGF (Supplementary Fig. 3A), in
keeping with the chequerboard analysis that demonstrated apo(a) chemorepellent
activity  was independent of PDGF (Fig. 1C). To examine the role of ROCK, SV-SMC
were  pre-treated with 10 M Y-27632 (pharmacological ROCK inhibitor), before
performing  Boyden chamber assays (Fig. 5C). Consistent with the RhoA knock down
experiments, inhibition of ROCK had no effect on basal migration but prevented the
effects of apo(a). Again, similar results were obtained for apo(a)-induced migration
in  the presence of PDGF (Supplementary Fig. 3B).
Supplementary data related to this article found, in the online version, at
http://dx.doi.org/10.1016/j.biocel.2013.05.021.
3.4. Statins attenuate the effects of apo(a)
Statins exhibit multiple pleiotropic effects, one of which is inhibition of RhoA
prenylation  and activity, as a downstream consequence of HMG  CoA reductase
inhibition  (Porter and Turner, 2011). As SV-SMC migration in response to PDGF is
known to be modulated by statins (Corpataux et al., 2005), and we had consistently
demonstrated  that apo(a) exhibited chemorepellent activity independently of PDGF
(Fig. 1C), we explored the effects of statins on SV-SMC migration in the absence
of  PDGF. SV-SMC were pre-treated with 1 M ﬂuvastatin for 2 h prior to use in
1780 K. Riches et al. / The International Journal of Biochem
Fig. 3. Effects of apo(a) are TGF- and ERK-independent. (A) Cells were pre-treated
with  0.3–30 g/mL TGF RII neutralising antibody (Ab) for 1 h, stimulated with
5 ng/mL TGF for 20 min and lysates immunoblotted for phospho-Smad2 and -
actin. (B) Number of migrated cells per HP ﬁeld in response to PDGF and apo(a)
following  pre-treatment with 10 g/mL TGF RII neutralising antibody (n = 3). Hor-
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pzontal dashed line represents effect of PDGF alone. (C) Cells were treated with apo(a)
or 5–30 min  and lysates immunoblotted for phospho-ERK and total ERK (n = 3).
umbers refer to densitometry data (mean ± SEM).
oyden chamber assays. Fluvastatin had no effect on basal migration, but markedly
ttenuated  the directional effects of apo(a) (Fig. 5D).
.5.  Apo(a) acts via integrin ˛Vˇ3 and tyrosine kinases
To determine whether V3 integrin activity accounted for the effects of apo(a)
n  SV-SMC, cells were pre-treated with 5 g/mL mouse anti-human neutralising
ntibody  against integrin V3 prior to the Boyden chamber assay. Blocking V3
ntegrin had no effect on basal cell migration, however it reduced the directional
ffects  of apo(a) by 72% (Fig. 5E). Tyrosine kinase signalling pathways lie down-
tream of V3 integrin, and accordingly pre-treatment with a general tyrosine
inase  inhibitor (genistein, 100 M)  also reduced the directional effects of apo(a)
y  65% (Fig. 5F), analogous to that of V3 inhibition.
. Discussion
SMC  migration is central to the pathogenesis of numer-
us cardiovascular processes, including vessel wall remod-
lling/adaptation and atherosclerosis (Gerthoffer, 2007). This is the
rst report of a chemorepellent effect of apo(a) on vascular SMC.
hilst chemoattraction is common in SMC, the contribution of
hemorepellent cues has been largely overlooked although it is not
ithout precedent (Liu et al., 2006).
Apo(a) has previously been reported in vitro to enhance SMC
igration (O’Neil et al., 2004). This is in contrast to our results, an
nconsistency that may  be explained by differences in experimental
rotocol. O’Neil et al. exposed SMC  to apo(a) for 96 h prior to (butistry & Cell Biology 45 (2013) 1776– 1783
not  during) migration assays whereas we  exposed cells to apo(a)
only at the point of, and during the assay. Our data indicate that
apo(a) acted as a chemorepellent in both aortic and venous SMC
from different patients, however O’Neil et al. used commercially
available SMC  from a single source. Nevertheless the Boyden cham-
ber assays clearly demonstrate that SMC  motility is dysfunctional in
the presence of apo(a), an effect that would potentially impair vas-
cular function through increasing vessel wall stiffness. Apo(a) alone
acted in a potent chemorepellent manner. In support of its actions
as a chemorepellent, the only occasion where apo(a) enhanced
migration to PDGF was  when apo(a) and PDGF were in opposing
chambers of Boyden assays. The increased migration observed in
this case was likely the net effect of chemorepulsion from apo(a)
in the upper chamber in addition to the chemoattractant cues of
PDGF in the lower chamber.
The  functional effect of apo(a) appears to vary depending on
the vascular bed, for example its ability to induce divergent adhe-
sion molecule expression in endothelial cells (recently reviewed in
Riches and Porter, 2012). Our data herein suggest that acute expo-
sure to apo(a) is chemorepulsive to human SMC  of both arterial
and venous origin although the mechanism of action is undoubt-
edly complex and involves multiple signalling pathways, including
integrin V3. It is feasible that the magnitude of apo(a) effect
could be governed by differential expression and activation of vari-
ous signalling pathways in particular subsets (phenotypes) of SMC
within vascular walls. The validity of such a hypothesis is upheld
by studies in which SMC  diversity in atherosclerotic plaques and
restenotic lesions has been demonstrated (Adams et al., 2006;
Zhang et al., 2002).
Effective  adaptation to arterial environments early after implan-
tation is a key determinant of the long-term patency of vein
grafts (Owens, 2010), where the consequences of increased ves-
sel wall stiffness may  be deleterious. Following surgical grafting,
the SV must adapt to a new role in a process often referred to as
‘arterialisation’. This process requires signiﬁcant expansive remod-
elling; a process in which SMC  phenotypic modulation is key. SMC
exhibit increased motility and decreased contractility during this
initial adaptive process (Borin et al., 2009; Mehta et al., 1998). The
effects of apo(a) on SMC  that we  revealed in this study are there-
fore of potential signiﬁcance to the fate of the adapting graft. We
propose that transient increases in exposure to apo(a) following
CABG, would act as a chemorepellent to SMC  and compromise
their capacity to remodel and “arterialise” the venous graft. Pro-
longed exposure to high circulating apo(a) levels would render the
cells more stationary and contractile, exacerbating their inability to
form an arterial conduit. Importantly, this adaptive phase is tem-
porally distinct from subsequent maladaptive intimal thickening
and occlusion (Wong et al., 2008). SV grafts are prone to early lipid
retention and it is already well established that LDL plays a key role
in the failure of grafts to remodel (Shi et al., 2001). Histological stud-
ies have reported deposition of Lp(a) in resected SV grafts (Cushing
et al., 1989), suggesting a similar functional role to that of native
LDL. Two  further studies have quantiﬁed plasma levels of Lp(a) in
patients with vein grafts and observed elevated levels in those with
stenosis versus non-occluded grafts. One of these documented lev-
els of 32 mg/dL versus 17 mg/dL respectively (Hoff et al., 1988); and
the other 24 mg/dL versus 12 mg/dL respectively (Pokrovsky et al.,
2003). The maximum concentration of apo(a) used in our study was
50 nM (equivalent to 1.4 mg/dL apo(a) or approx. 0.5 mg/dL whole
Lp(a)), indicating potent effects directly upon SV-SMC.
In  native atherosclerosis, SMC  are key constituents of ﬁbrous
plaques and are responsible for promoting plaque stability through
proliferation and migration (Fernandez-Hernando et al., 2009).
Aberrant SMC  migration provoked by high circulating Lp(a) lev-
els would plausibly lead to fewer SMC  in atherosclerotic plaques,
disrupting morphology and conferring vulnerability to rupture.
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Fig. 4. Effect of apo(a) on cell morphology, -SMA expression and RhoA activation. (A) SV-SMC were treated with apo(a) for 24 h, ﬁxed and stained with rhodamine phalloidin
(F-actin, yellow) and TOTO-3 (cytoplasm/nuclei, red). Actin ﬁbres were detected using Harmony software. Scale bar = 20 m. (B) Spread cell area measurements, (C) F-actin
stain  intensity and (D) morphology. Ridges indicate actin bundling (all n = 200 cells, ***P < 0.001). (E) Cells were treated with 25 nM apo(a) for 6–48 h and lysates immunoblotted
for -SMA and GAPDH (n = 4). Numbers refer to densitometry data (mean ± SEM). (F) RhoA activation in response to apo(a) (n = 8, **P < 0.01 ANOVA for effect of apo(a). Post
hoc  *P < 0.05 vs 0 min). Mean activity levels were 10.9 ± 2.5 pg GTP-bound RhoA per g total cellular protein in unstimulated samples and 16.3 ± 3.9 pg following 20 min
apo(a) exposure. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Mechanism of apo(a)-induced effects. (A) SV-SMC were transfected with 25 nM RhoA siRNA; knockdown was  conﬁrmed via immunoblotting. Numbers represent
densitometry data for RhoA (n = 6). (B) Number of migrated cells per HP ﬁeld under basal conditions and in response to apo(a) following RhoA silencing (closed bars) compared
to  mock transfected cells (open bars, n = 5). (C). Migration under basal conditions and in response to apo(a) following pre-treatment with vehicle control (0.002% dH2O; open
bars)  or 10 M ROCK inhibitor, Y-27632 (closed bars) for 1 h (n = 6). (D) Migration in response to apo(a) following pre-treatment with vehicle control (0.001% dH2O; open
bars) or 1 M ﬂuvastatin (closed bars) for 2 h (n = 5). (E). Migration in response to apo(a) following pre-treatment with vehicle control (0.001% PBS; open bars) or 5 g/mL
v3 integrin neutralising antibody (closed bars) for 5 min  (n = 5). (F) Migration in response to apo(a) following pre-treatment with vehicle control (0.001% DMSO;  open
bars) or 100 M genistein (closed bars) for 1 h (n = 5). ***P < 0.001, **P < 0.01, *P < 0.05, NS = non-signiﬁcant.
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Fig. 6. Summary ﬁgure. Our data suggest that apo(a) interacts with integrin V3 on the surface of vascular SMC. This signals through tyrosine kinases to activate RhoA
and induce stress ﬁbre formation, cell spreading and chemorepulsion. These molecular effects may  have a negative impact on smooth muscle cell remodelling contributing
towards atherosclerosis, vessel stiffness, and impaired vein graft integration and arterialisation.
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tThe lack of an identiﬁed Lp(a) receptor has not hindered research
nto the signalling pathways by which it operates. Its actions have
ometimes been attributed to inhibition of TGF activation (e.g.
timulating cell proliferation (O’Neil et al., 2004; Liu et al., 2009));
owever the novel chemorepellent effect that we observed was
ndependent of this mechanism. Not only did the short time-frame
f action (<6 h) of apo(a) suggest that this was unlikely, inclusion of
 neutralising antibody to TGF RII did not modulate the migratory
esponse. Similarly, apo(a) was previously shown to potently and
ransiently activate ERK phosphorylation (Liu et al., 2009), yet our
ata demonstrate that this pathway is not activated above basal
evels in SV-SMC, nor did we observe any modulation of PDGF-
nduced ERK phosphorylation by apo(a). Whilst a cognate Lp(a)
eceptor remains elusive, apo(a) has been shown to signal via the
V3 integrin in HUVEC (Liu et al., 2009). Our study reveals that this
athway is also functional in SV-SMC, although the downstream
ffectors are different. In HUVEC, signalling through V3 integrin
nduced activation of ERK, whereas in SV-SMC tyrosine kinase and
hoA pathways are apparently the predominant signalling compo-
ents.
RhoA and its downstream effector, ROCK, are directly involved in
tress ﬁbre formation and accordingly, acute exposure of SV-SMC
o apo(a) induced activation of RhoA. This concurs with previous
tudies in HUVEC (Cho et al., 2008). Exposure of SV-SMC to apo(a)
esulted in an increase in the frequency of stress ﬁbre bundles and
 notable increase in spread cell area, however it is unlikely that
po(a) was altering SMC  phenotype as we did not detect any change
n -SMA expression levels. Transfection of SMC  with RhoA siRNA
r pre-treatment with ROCK inhibitor prior to the Boyden chamber
ssay had no effect on basal or PDGF-induced migration. This is in
eeping with previous studies in human and rat aortic SMC  in which
ac rather than RhoA was important for PDGF-induced migra-
ion (Ryu et al., 2002). RhoA/ROCK inhibition completely negated
he effects of apo(a), indicating that its chemorepellent effects onSV-SMC were, at least in part, mediated via RhoA/ROCK; both of
which are well recognised to have negative effects on the vascula-
ture in pathological conditions (Sawada et al., 2000).
Statins are routinely prescribed as cholesterol-lowering drugs,
but are also known to exhibit properties that are independent of
lipid-lowering (pleiotropism), many of which are attributable to
inhibition of small G-protein prenylation (e.g. RhoA and Rac) (Laufs
et al., 2002; Porter and Turner, 2011). The inﬂuence of statin treat-
ment on absolute plasma Lp(a) is contentious, with no consistently
reported effect on circulating levels (Hunninghake et al., 1993;
Joy et al., 2008; Kostner et al., 1989). Therefore, although statins
do not appear to modulate circulating levels of Lp(a) per se, they
hold potential to negate the adverse functional effects of apo(a)
on SMC, through inhibition of RhoA activity. Indeed, graft patency
rates in patients with high serum Lp(a) receiving statin therapy
were reportedly superior to those of patients not receiving statins
(Pokrovsky et al., 2003).
Plasma  concentrations of Lp(a) remain relatively constant
throughout life, however levels are reported to rise acutely under
pathological challenge for example after myocardial infarction
(MBewu et al., 1993; Tsimikas et al., 2003), percutaneous coro-
nary intervention (Tsimikas et al., 2004) and plausibly therefore
after SV bypass grafting. Under these circumstances it appears that
Lp(a), acting as an acute phase reactant, impairs the crucial ability
of vascular SMC  to remodel and adapt appropriately.
In conclusion, we have demonstrated that the apo(a) moiety of
human Lp(a) confers distinct functional effects on SMC  that may
impair adaptive remodelling (summarised in Fig. 6). Our  study has
identiﬁed V3 and RhoA as potential therapeutic targets to alle-
viate the perceived detrimental effects of Lp(a) on vascular SMC  in
cardiovascular pathologies. Development of speciﬁc therapeutics
to Lp(a) is an area of focussed interest (Tsimikas and Hall, 2012), and
statins may  partly fulﬁl this role through their pleiotropic effects
on small G-proteins.
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